Clinical Trial: Efficacy and safety of tafasitamab and lenalidomide (TAFA_LEN) in combination with the R-CHOP regimen for the treatment of newly diagnosed intermediate-high-risk diffuse large B-cell lymphoma (China)

China, Oct. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety of tafasitamab and lenalidomide (TAFA_LEN) in combination with the R-CHOP regimen for the treatment of newly diagnosed intermediate-high-risk diffuse large B-cell lymphoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134208

Registration Time: 2026/10/12

Type: Interventional study

Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=347048

Published by HT Digital Content Services with permission from Health Daily Digest....